Skip to main content
    F

    Fortress Biotech Inc (FBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.71
    -0.17 (-9.04%)

    Market Cap: $62.70M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Fortress Biotech Inc (FBIO) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Fortress Biotech (FBIO) trades at 0.7x trailing earnings and 0.8x sales. Its P/B of 0.4x is below its 5-year median of 1.8x. Its forward P/E is 1.2x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 41.7% lower over the next year.

    MultipleValue
    P/E (trailing)0.7x
    Forward P/E1.2x
    Price to sales0.8x
    Price to book0.4x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 85.2% below 2.7x.

    MultipleCurrent5-year median10-year median
    P/B0.4x1.8x2.7x
    Medians of month-end values through Oct 2026: 55 months (5-year) and 110 months (10-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 0.7x in 2024 to 5.0x in 2020.

    Year endPriceP/EP/SP/B
    2025$3.66N/A2.0x20.5x
    2024$2.03N/A0.7x1.8x
    2023$3.01N/AN/A1.0x
    2022$9.82N/AN/A11.3x
    2021$37.489.8x3.1x2.2x
    2020$47.53N/A5.0x2.5x
    2019$38.53N/AN/A5.8x
    2018$12.89N/A1.4x20.0x
    2017$59.82N/A1.2x3.1x
    2016$40.48N/A2.4x2.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About FBIO

    What is FBIO's forward P/E ratio?

    Fortress Biotech has a forward P/E ratio of 1.2x.

    Is FBIO stock overvalued?

    GNG's valuation label for FBIO is Undervalued.

    What is FBIO's price to sales ratio?

    Fortress Biotech has a price to sales ratio of 0.8x.